Company Filing History:
Years Active: 2024
Title: Deling Wang: Innovator in RNAi Therapeutics for COVID-19
Introduction: Deling Wang is a distinguished inventor based in Jiangsu, China, recognized for his pioneering work in the field of therapeutics for respiratory infections. With a focus on the global health crisis posed by the 2019 novel coronavirus (2019-nCoV), Wang's innovations have contributed significantly to the fight against COVID-19.
Latest Patents: Deling Wang holds a patent for "Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)." This patent encompasses compositions and methods designed for the development of potent siRNA therapeutics aimed at preventing and treating COVID-19 infections. The compositions include a pharmaceutical formulation comprising siRNA cocktails that specifically target critical viral genes, employing pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. The patent also details various administration methods, such as airway instillation, subcutaneous injections, and nebulizer aerosolization, providing a robust framework for effective delivery.
Career Highlights: Deling Wang is currently associated with Sirnaomics, Inc., where he continues to innovate and advance research in RNAi technologies. His expertise in developing novel siRNA therapeutics showcases his commitment to addressing urgent public health challenges. With one patent to his name, Wang is establishing himself as a key player in the realm of antiviral therapeutics, particularly during the ongoing pandemic.
Collaborations: Throughout his career, Deling Wang has collaborated with notable professionals in his field, including Danny Tang and Xueping Chen. Their joint efforts contribute to the broader research initiatives aimed at enhancing the efficacy of RNAi therapeutics and addressing the complexities surrounding viral infections.
Conclusion: Deling Wang’s contributions to the field of RNAi therapeutics demonstrate the critical role innovation plays in combating health threats like COVID-19. His research, encapsulated in his patent, provides a valuable resource in the pursuit of effective treatments. As a member of Sirnaomics, Inc., Wang continues to work alongside esteemed colleagues, shaping the future of therapeutic interventions and paving the way for advancements in medical science.